anti-IL8 mAb clinical trials

A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers

This study is testing a new medicine, BMS-986253, alongside existing cancer treatments (Nivolumab and Ipilimumab) for advanced cancers. Doctors want to see how safe the combined medicines are and if they help shrink tumors. It's an early-stage study to gather important information.